

Homework

Use the following regimen to complete the following case study information. The answers will be reviewed and discussed during the Review session.

Hyper-CVAD/MTX-Ara-C

Course 1:

- Cyclophosphamide 300mg/m² over 3 hours every 12 hours for 6 doses on day 1 (8/1/17), day 2 (8/2/17), & day 3 (8/3/17). Start first dose at 8am.
- Doxorubicin 50mg/m² over 48 hours on day 4 (8/4/17) at 8am.
- Vincristine 2mg over 15 minutes on day 4 (8/4/17) at 8am. Repeat on day 11 (8-11-17) at 8am.
- Dexamethasone 40mg/day IV on day 1 (8/1/17), day 2 (8/2/17), day 3 (8/3/17) and day 4 (8/4/17) and day 11 (8/11/17), day 12 (8/12/17), day 13 (8/13/17), and day 14 (8/14/17). Administer 30 minutes prior to chemotherapy.
- Filgrastim 5mcg/Kg subq daily until ANC > 500. Start day 8 (8/8/17) at 8am.

Course 2:

- Methotrexate 200mg/m² over 2 hours IV on day 1 (9/5/17) at 8am
- Methotrexate 800mg/m² over 22 hours on day 1 (9/5/17) at 10am
- Cytarabine 3,000mg/m² IV over two hours every 12 hours for 4 doses on day 2 (9/6/17), and day 3 (9/7/17). First dose at 8am.
- Leucovorin 50mg IV every 6 hours until MTX level <50nM. Start day 2 (9/6/17) at 8pm.
- Filgrastim 5mcg/Kg subq daily until ANC > 500. Start on day 4 (9/8/17) at 8 pm.

1. Calculate the doses for all medications using actual body weight

- Bob Taylor is 6 ft 3 in tall and weighs 270 pounds
- Sarah Adams is 5 ft 1 inch tall and weighs 90 pounds

	Bob dose	Sarah dose
Course 1:		
Cyclophosphamide 300mg/m ²		
Doxorubicin 50mg/m ²		
Vincristine 2mg		
Filgrastim 5mcg/Kg		
Course 2:		
Methotrexate Bolus 200mg/m ²		
Methotrexate Infusion 800mg/m ²		
Cytarabine 3,000mg/m ²		
Filgrastim 5mcg/Kg		

2. For each chemotherapeutic agent in the regimen list:

- 2 pretreatment physical assessments
- 2 labs, diagnostic studies
- 1 indication dose reduce or hold the dose
- 2 components of patient/ family education for each agent

	2 Physical Assessments	Labs &/or Diagnostic Studies	Variables to Reduce or Hold Dose	2 Patient/ Family Education Aspects
Course 1				
Cyclophosphamide				
Doxarubicin				
Vincristine				

	Physical Assessments	Labs &/or Diagnostic Studies	Variables to Reduce or Hold Dose	Patient/ Family Education
Course 2				
Methotrexate				
Cytarabine				
Leucovorin				

3. List 2 co-morbid conditions may impact the patient’s ability to receive full doses of each of these agents or at least require closer monitoring?

1.

2.

4. On the attached calendars write in the schedule, including start times, for all agents.

Course 1

August 2017						
Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
	1	2	3	4	5	6
7	8	9	10	11	12	13
14	15	16	17	18	19	20
21	22	23	24	25	26	27
28	29	30	31			

Course 2

September 2017						
Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	